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DockingAbstract A three-dimensional quantitative structure–activity relationship (3D-QSAR) study was
performed on 1,3,5-triazine derivatives which were based on Ala16Val + Ser108Thr mutant DHFR
inhibitors of Plasmodium falciparum clone (FCR-3). Comparative Molecular Field Analysis
(CoMFA) was carried out for designing novel PfDHFR enzyme inhibitors. It is shown that the
steric and electrostatic properties by CoMFA contours can be related to the PfDHFR inhibitory
activity. Glide-XP of Schro¨dinger was used for docking of PfDHFR inhibitors into the putative
binding sites of the PfDHFR.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.1. Introduction
Malaria is one of the most widespread diseases in the world.
According to WHO estimates 40% of the world’s populations
presently live under malarial threat. Around 300 and 500 mil-
lion cases of malaria occur annually, leading to 1–3 million
deaths.1 Its control is globally a high priority task. Although
effective antimalarial agents have been known for a long time,the alarming spread of drug resistant strains of Plasmodium
falciparum, which is the most lethal parasite species, undergoes
the urgency and continuous need for the discovery of new ther-
apeutics. A major initiative in this direction is to ﬁnd enzyme
targets that are critical to the disease process or essential for
the survival of the parasite. Identiﬁcation and design of novel
chemical entities speciﬁcally affecting these targets could lead
to better drugs for the treatment of malaria.2 The widespread
occurrence of malaria could be attributed to the development
of resistance of the parasite to the available antimalarial drugs
such as chloroquine, cycloguanil and pyrimethamine. These
drugs have been used clinically in the treatment of malaria,
especially to P. falciparum malaria for longer period of time.
But due to the emergence of drug-resistant parasite in many
countries, there is need of new and effective drugs for treat-
ment of malaria.3–8
126 P.N. Dube et al.The dihydrofolate reductase (DHFR) domain of a
bi-functional enzyme which is known as dihydrofolate
reductase-thymidylate synthase (DHFR-TS) is one of the well-
established drug targets in P. falciparum. It catalyzes
NADPH-dependent reduction of 7,8-dihydrofolate (DHF) to
5,6,7,8-teterahydrofolate (THF) that plays a crucial role in
many biochemical processes such as folate metabolism and
DNA synthesis. Thus, inhibition of DHFR causes interruption
of DNA formation which ultimately results in death of the par-
asitic cells. This observation has been exploited to design anti-
malarial agents that inhibit the normal function of PfDHFR
enzyme.9–12 It is a speciﬁc target for type-2 anti-folates such as
pyrimethamine and cycloguanil.13 These antimalarial drugs
selectively inhibit PfDHFR enzyme without affecting the corre-
sponding enzyme in humans. However, due to point mutations
at amino acid residues 16, 51, 59, 108 and 164 in the active site of
PfDHFR enzyme, the therapeutic values of cycloguanil and
pyrimethamine have dramatically declined in many parts of
the world.14,15 Such mutations decrease the optimal binding
interactions of the drugs and amino acid residues in the active
site of PfDHFR enzyme which result in reduction of efﬁcacy.16
Computer-aided drug design approaches such as pharma-
cophore mapping, docking, homology modeling and quantita-
tive structure–activity relationships (QSAR) models17–20 are
some of the approaches which have been employed in
understanding parasitic drug resistance, and also in designing
antimalarial drug candidates for inhibition of drug-resistant
P. falciparum parasite.
Two of the most widely used 3D-QSAR approaches are
based on Comparative Molecular Field Analysis (CoMFA)21
and Comparative Molecular Similarity Index Analysis (CoM-
SIA).22 In CoMFA model, the steric and electrostatic ﬁelds are
computed based on 3D-structures of ligands in the training set.
Partial Least Square (PLS) is then used to derive an equation
that correlates the biological activity with the different probes
at various lattice points. Different color-coded contour maps
surrounding the ligands give insights about favorable and
unfavorable ligand–receptor interactions, and also used as
guides for designing novel leads. Molecular docking study
was carried out to know the possible interaction between
DHFR and title compounds.
2. Results and discussion
2.1. Molecular alignment and model generation
The compounds selected for the 3D-QSAR analysis and their
estimated biological activities are listed in Table 1. The 28
compounds were used in the 3D-QSAR analysis. Among the
data set used, only 20 molecules were included in the training
set and the remaining 08 molecules were used as test set. The
choice of compounds as training and test set was performed
randomly. The statistic results of CoMFA models were con-
structed by the minimum energy conformer-based alignment.
2.2. Statistical analyses
The CoMFA model with the highest external predictive ability
(r2pred = 0.740) was selected as the best model. The training set
compounds used to generate this model, and the test set com-
pounds are given in Table 1. The cross-validation coefﬁcient,r2cv, and the non-cross validate coefﬁcient, r
2
ncv, of this model
were found to be 0.656 and 0.996, respectively, for optimum
number of components (ONC) 6. The standard error of
estimation (SEE) of this model was 0.033. The summary of
statistics of the best CoMFA model is given in Table 2. The
relative contributions of steric and electrostatic ﬁelds 76.7%
and 23.3%, respectively, indicate that steric interactions are
the major contributors for the variation of biological activities
of triazine derivatives used in the study.
The schematic representation showing the relative positions
of Val16, Thr108 and Asp54 in the active site of Ala16Val +
Ser108Thr mutant P. falciparum parasite is given in Fig. 1
whereas the conformation of pyrimethamine bound in the active
site of X-ray crystallographic structure of double mutant
(S108N+ C59R) PfDHFR (Fig. 2). As shown in Fig. 2, the
para-chloro phenyl ring of pyrimethamine was displaced from
aplanewhichwas perpendicular to the plane of the 2,4-diamino-
pyrimidine ring. Similar displacement alsooccurs in the p-chloro
phenyl ring of cycloguanil which results in loss of its binding
interactions and afﬁnity in the active site of Ala16Val + -
Ser108Thr mutant enzyme as compared to that of the wild type.
As indicated in Table 2, the predictive correlation coefﬁcient
(r2pred = 0.740) was reasonable to suggest that our model is a
satisfactory model with good predictive ability. A high r2 value
(0.999) of bootstrapping which was carried out at 100 runs also
supports the statistical validity of the model.23,24 The summary
of statistics of the CoMFA studies is given in Table 2.
The comparison between the experimental and predicted
activities of the training set and test set compounds (Table 3)
indicated that the CoMFA models show good predictive abil-
ities as demonstrated by the small residual values of both sets
of compounds. Fig. 3 shows the graph of predicted vs. exper-
imental activities of the training and test set compounds. The
linearity of the graphs also indicates that both the CoMFA
(Fig. 3(A)) models are predictive enough to be used as guides
in designing new molecules.
2.3. Contour map analyses
Having obtained a valid CoMFA model, it is possible to iden-
tify regions of space around the molecules where changes with
altering substitution would lead to an increase or a decrease in
biological activity. This has been achieved by using a CoMFA
contour map for the model, as shown in Fig. 4(a) (steric con-
tributions) and in Fig. 4(b) (electrostatic contributions).
2.3.1. Visual inspection of 3D contour maps generated by
CoMFA
The CoMFA steric and electrostatic maps of triazine deriva-
tives used in the study are depicted in Fig. 4 along with the
most active compound (16.10) displayed in the background.
In these contour maps, the green contours show the regions
where sterically bulkier groups are associated with increase
in biological activity. On the other hand, yellow contours indi-
cate the regions where such bulkier groups lower biological
activities of ligands.25 For the selected best CoMFA model,
green contours were observed near 30-substituent of 5-aryl
ring and at about three C–C bonds away from C6 atom of
the 1,3,5-triazine ring (Fig. 4(a)). The green regions show that
increasing steric bulk at these positions results in increased bio-
activities of triazine-derivatives. This is consistent with the fact
Table 1 Data set of compounds used for 3D-QSAR studies.
NN
N
H
N
H
R2
R1
NH2
Ar
.
Comp. No. R1 R
2 Ar Exp. IC50 (lM) Exp. pIC50
16.1 –CH3 –CH3 49.75 4.3032
16.2 9.89 5.0048
16.3 –CH3 –CH3 Cl 16.55 4.7812
16.4 –H
O2N
Cl
Cl
11.12 4.9539
16.5 –H
F
Cl
Cl
8.41 5.0752
16.6 –CH3 –CH3
O Cl
11.33 4.9469
16.7 –H
O Cl
7.11 5.1481
16.8 –H
OCl
Cl
6.73 5.1720
16.9 –H
O
Cl
Cl
Cl 4.32 5.3645
16.10 –H
O
O Cl
0.99 6.0044
16.11 H
O2N O Cl
7.39 5.1314
(continued on next page)
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Table 1 (continued)
Comp. No. R1 R
2 Ar Exp. IC50 (lM) Exp. pIC50
16.12 H
Cl
O Cl
6.66 5.1765
16.13 –H
O Cl
4.59 5.3382
16.14
O Cl
7.94 5.1002
16.15 –H
H3CO O Cl
6.66 5.1765
16.16 –H
N O Cl
44.75 4.3492
16.17 –H
F O Cl
6.21 5.2069
16.18 –H
F3C O Cl
5.54 5.2565
16.19 –H
S Cl
1.30 5.8861
16.20 –CH3 –CH3
S Cl
7.84 5.1057
16.21 –H
O
Cl 4.53 5.3439
16.22 –H
O
Cl
Cl
4.52 5.3449
16.23 –H
O
F 10.85 4.9646
16.24 –H
O NO2
3.87 5.4123
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Figure 1 The schematic representation of the relative orienta-
tions of Val16, Thr108 and Asp54 in the active site of
A16V + S108T mutant PfDHFR enzyme.
Figure 2 The conformation of pyrimethamine bound in the
active site of X-ray crystallographic structure of double mutant
(S108N+ C59R) PfDHFR enzyme (1J3J.pdb).
Table 1 (continued)
Comp. No. R1 R
2 Ar Exp. IC50 (lM) Exp. pIC50
16.25 –H
O OCH3
12.31 4.9097
16.26 –CH3 –CH3
O Cl
7.20 5.1427
16.27 –H
O Cl
2.71 5.5670
16.28 –H
O
Cl 1.36 5.8665
Table 2 Summary of CoMFA model statistics.
NOC r2cv r
2
bs r
2
ncv F-test SEE r
2
pred PRESS Field Contribution
S E
6 0.656 0.999 0.996 562.55 0.033 0.740 1.312 76.7 23.3
S: steric; E: electrostatic; r2pred: predictive correlation coefﬁcient; ONC: optimum number of components; r
2
cv: cross-validated correlation
coefﬁcient; r2ncv: conventional correlation coefﬁcient; SEE: standard error of estimation; F-value: F-test value; PRESS: predicted residual sum of
squares of test set molecules.
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substituents either at C6- or the meta-position of the 5-aryl
ring. Some compounds also have bulky substituents at both
positions.
Compound 16.10 bears cyclic ring i.e. furan substituent at
their C6-positions, and show highest anti-plasmodial activities
(pIC50 > 5.70) compared to cycloguanil as demonstrated by
their high pIC50 values of 6.004. Though it has benzene substi-
tuent at their C6-positions, 16.19 and 16.28 have high activity.
This observation could be attributed to the fact that the 19-Cl
substituent favorably interacts with the enzyme’s active site to
enhance inhibitory activity and helps to reduce the unfavorable
effect of 27-Cl substituent.On the other hand, compounds which belong to no steri-
cally bulky substituents fall in the above mentioned green
regions. These compounds generally exhibit low activities
(pIC50 < 4.8). Even though they have dimethyl and dimethyl-
amine substituents at C6-position of the triazine ring,
compounds 16.1, 16.3 and 16.16 show low activities. This
Table 3 Comparison between the experimental and predicted
activities (pIC50) of the training set and test set compounds for
CoMFA models.
Comp. No. Experimental pIC50 Predicted pIC50 Residual
16.1 4.3032 4.313 0.0098
16.2 5.0048 5.024 0.0192
16.3 4.7812 4.804 0.0228
16.4a 4.9539 5.590 0.6361
16.5 5.0752 5.030 0.0452
16.6 4.9469 4.944 0.0019
16.7a 5.1481 4.953 0.1951
16.8a 5.1720 5.364 0.1920
16.9 5.3645 5.387 0.0225
16.10 6.0044 6.004 0.0004
16.11a 5.1314 5.210 0.1786
16.12 5.1765 5.134 0.0425
16.13 5.3382 5.381 0.0428
16.14a 5.1002 5.350 0.2498
16.15 5.1765 5.163 0.0135
16.16 4.3492 4.347 0.0022
16.17a 5.2069 5.155 0.0519
16.18a 5.2565 5.371 0.1145
16.19 5.8861 5.893 0.0069
16.20 5.1057 5.080 0.0257
16.21 5.3439 5.352 0.0081
16.22 5.3449 5.313 0.0319
16.23 4.9646 4.994 0.0294
16.24a 5.4123 5.236 0.1763
16.25 4.9097 4.905 0.0047
16.26 5.1427 5.154 0.0113
16.27 5.5670 5.574 0.0070
16.28 5.8665 5.857 0.0095
a Test set of molecules.
130 P.N. Dube et al.could be attributed to the fact that the bulky groups do not fall
into the green region. To fall into this region, the length of the
bulky group should be about three C–C bonds away from the
1,3,5-triazine ring (or C6 atom) and also another group should
be located at 19- position of the 5-aryl ring of triazine deriva-
tives (Fig. 4(a)).
The CoMFA electrostatic interaction contour maps
(Fig. 4(b)) are represented by red and blue regions. The red
contours represent regions where electron-rich (electronega-
tive) groups result in enhanced bioactivity whereas blue con-
tours correspond to regions where increased positive charge
(or decreased negative charge) would result in an enhancedFigure 3 CoMFA graphs of predicted versus experimentalbiological activity. Three small red contours near 30-Cl substi-
tuent, and other two small red contours on C6-substituent at
about C–C length distance from C6 atom were observed
(Fig. 4(b)). Comparison of the activities of 16.10 vs. 16.1,
16.28 vs. 16.23 demonstrated that an electronegative Cl substi-
tuent at the 19-position could contribute to the observed high
activities of these compounds. Hence, higher activities of
16.10, 16.19 and 16.28 could be attributed to the presence of
19-Cl substituent that falls into the red region.
In this study no compound was found to possess an elec-
tron-deﬁcient substituent near the blue regions. The analysis
of the CoMFA contour maps also indicated that the most ac-
tive compounds have bulky and electronegative substituents or
at least one of them properly oriented, respectively, at the ste-
rically and electrostatically favorable regions. Occurrence of
the green and red contours together suggests the need of both
sterically bulky and electron rich substituents in order to in-
crease inhibitory activities of triazine analogs.
2.4. Docking analysis
A docking study could offer more insight into understanding
the protein–inhibitor interactions and the structural features
of active site of protein. Beginning of the docking, it is neces-
sary to validate the docking reliability. The ligand pyrimeth-
amine of the crystal structure of PfDHFR complex as a
temple was adopted to perform the validation.17,26 The ligand
pyrimethamine was ﬂexibly re-docked to the binding site of
PfDHFR (PDB ID 1J3J) and the docking conformation corre-
sponding to the lowest energy score was selected as the most
probable binding conformation. As a result, the re-docked
pyrimethamine and crystal structure pyrimethamine of 1J3J
complex are almost at the same position in the active site
and the RMSD for all atoms of the two conformers is
0.72 A˚, suggesting a high docking reliability of Glide XP.
Therefore, the Glide docking protocol and the used parameters
could be extended to search the binding conformations to
PfDHFR for other inhibitors.
The active site contains the highly conserved residues
Asp54, Ala16, Ser120, Ser122, Phe123, Asn124, Phe224,
Gly225, Leu119, Phe258, Ile310, Val311, Leu314, Phe315,
Gly165, Phe319, Ser380, Ile386, Arg122, consistent with sev-
eral homology modeling studies.27–29 Using Glide docking,
all compounds selected from CoMFA study were docked into
the putative binding sites of PfDHFR enzyme. The binding
score (Gscore) and Glide XP terms of all the compounds are
depicted in Table 4. It should be noticed that the G-ScorespIC50 values of training (A) and test set (B) molecules.
Figure 4 STDDEV*COEFF plots of the CoMFA steric (A) and electrostatic (B) contour maps. The most active molecule (16.10) is
displayed in the background. Green region: sterically favored; yellow region: sterically disfavoured; red region: negatively charged favored;
blue region: positively charged favored.
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The outcome of docking studies conﬁrmed that the results can
be used for the development of pharmacophoric features based
on Glide XP energetic terms.
Fig. 5(a) and (b) show the detailed binding mode between
the active sites of PfDHFR enzyme and the most active com-
pound 16.10 and the less active compound 16.1. Hydrogen-
bonds were also labeled to help understand the interactionsTable 4 Docking score and energetic terms generated by glide XP
Ligand GScorea Lipob Phobc HBondd
16.1 5.6 2.3 0.0 1.2
16.2 6.9 3.4 0.6 1.7
16.3 7.8 3.7 0.4 1.4
16.4 5.8 5.1 0.2 0.5
16.5 8.5 5.0 0.2 1.6
16.6 7.0 4.0 0.0 2.3
16.7 7.9 4.8 0.0 2.4
16.8 7.8 5.3 0.1 1.8
16.9 6.8 4.6 0.4 1.4
16.10 8.8 4.6 0.2 0.0
16.11 5.0 4.9 0.2 0.6
16.12 6.7 5.4 0.3 0.7
16.13 7.4 4.6 0.0 2.2
16.14 6.6 4.2 0.2 1.6
16.15 7.0 4.6 0.2 0.9
16.16 6.4 5.7 0.3 0.0
16.17 8.4 4.6 0.0 2.0
16.18 7.5 5.0 0.0 1.8
16.19 6.4 4.2 0.3 1.5
16.20 7.2 4.2 0.0 2.3
16.21 6.9 4.4 0.1 1.7
16.22 6.0 5.0 0.4 0.0
16.23 6.7 4.2 0.1 1.6
16.24 6.3 3.6 0.0 2.0
16.25 8.0 4.4 0.0 1.6
16.26 6.6 3.9 0.0 2.2
16.27 8.2 5.3 0.0 2.2
16.28 8.6 5.1 0.0 2.4
Pyrimethamine 8.1 4.2 0.1 1.6
a GScore Total GlideScore; sum of XP terms.
b Lipo Lipophilic term derived from hydrophobic grid potential and fra
c Phob Hydrophobic enclosure reward.
d HBond ChemScore H-bond pair term.
e Electro Electrostatic rewards; includes Coulomb and metal terms.
f Site SiteMap ligand-receptor non-H bonding polar-hydrophobic term
g MW Reward for ligands with low molecular weight.
h Penal Polar atom burial and desolvation penalties, and penalty for in
i RotPenal Rotatable bond penalty.of the complexes. Analyses of hydrogen-bond interactions con-
ﬁrmed that Ala16 and Gly165 play the relatively important
roles in binding potency (Fig. 5(a)). The side chain of Ala16
and the backbone of Gly165 are inclined to form the hydro-
gen-bonds with the hydrogen atoms of amino group at 2-posi-
tion of compound 16.10. The distances of the hydrogen-bonds
between compound 16.10 and amino acid residues of Ala16
and Gly 165 were 2.210 and 2.423 A˚, respectively. The anglesdocking.
Electroe Sitef MWg Penalh RotPenali
1.5 0.4 0.5 0.6 0.3
1.8 0.2 0.5 0.0 0.2
1.8 0.2 0.5 0.0 0.2
0.2 0.3 0.1 0.4 0.2
1.6 0.3 0.2 0.0 0.2
0.5 0.1 0.5 0.0 0.4
0.6 0.2 0.3 0.0 0.4
0.5 0.2 0.2 0.0 0.3
0.4 0.2 0.1 0.0 0.3
0.7 0.3 0.3 0.0 0.4
0.3 0.1 0.1 1.0 0.3
0.2 0.1 0.2 0.0 0.3
0.4 0.2 0.3 0.0 0.4
0.6 0.1 0.3 0.2 0.3
1.3 0.2 0.2 0.0 0.2
0.4 0.1 0.2 0.6 0.3
1.7 0.2 0.2 0.0 0.2
0.6 0.4 0.1 0.0 0.3
0.3 0.1 0.3 0.2 0.3
0.5 0.1 0.4 0.0 0.4
0.6 0.2 0.3 0.0 0.4
0.5 0.1 0.2 0.0 0.3
0.5 0.3 0.4 0.0 0.4
0.5 0.2 0.5 0.4 0.5
1.8 0.2 0.3 0.0 0.3
0.5 0.1 0.4 0.0 0.5
0.6 0.2 0.3 0.0 0.4
0.6 0.2 0.2 0.0 0.5
0.6 0.2 0.2 0.4 0.4
ction of the total protein ligand vdW energy.
s.
tra-ligand contacts.
Figure 5 Model of compound 16.10 (A) and 16.1 (B) docked into the binding site of PfDHFR. Important residues are shown as sticks.
132 P.N. Dube et al.of the two hydrogen-bonds were 168.60 and 150.24, respec-
tively. Similarly, the side chain of Asp54 formed a hydrogen-
bond with the hydrogen atom of amino group of compound
16.1, the distance and angle of the hydrogen-bond were
2.835 A˚ and 166.20, respectively. However, we have not ob-
served the hydrogen-bond between compound 16.1 and the
backbone of Ala16 and Gly165 (Fig. 5(b)).
3. Materials and methods
3.1. Data set
A data set of 28 triazine derivatives was used for the 3D-
QSAR study.30 The compounds were evaluated for their
in vitro anti-plasmodial activities of cycloguanil-resistant P.
falciparum clone harboring Ala16Val + Ser108Thr mutant
PfDHFR enzyme. The reported growth inhibition constant
(IC50) values were converted into corresponding pIC50 using
the formula-
pIC50 ¼  log IC50
pIC50 values were used for generation of the CoMFA model.
The reported IC50 values are given in the original literatures.
30
The selection of test and trainee sets was performed randomly.
The training set contains 20 and test set contains 08 compounds.3.2. Molecular modeling
All molecular modeling studies were carried out on SYBYL-X
1.3 (SYBYL-X 1.3, Molecular Modeling Software, Tripose
Inc., 1699).31 Since no bound ligand or crystal structure of
Ala16Val + Ser108Thr mutant PfDHFR enzyme was avail-
able, the lowest energy conformer of the most active compound
(16.10) was used as a template for proposition of the bioactive
conformation. This is a common approach in ligand based 3D-
QSAR studies in the absence of 3D-structural information of
the receptor or enzyme.32–34 A preliminary minimization was
performed on 16.10 to remove close atom or bad van der Waals
contacts by using 1000 cycle minimization with standard Tripos
force ﬁeld. A 0.005 kcal/mol energy gradient convergence crite-
rion using Powell’s method was also used as a ﬁnal step of en-
ergy minimization. To obtain the lowest energy conformer,
16.10 was then subjected to simulated annealing to heat the
molecule at 700 K for 1000 fs followed by annealing the mole-
cule to 200 K for 1000 fs.25,35 The resulting conformer with the
lowest potential energy was saved and subsequently used as a
template. All the remaining molecules were constructed based
on this template, and subjected to 1000 cycle minimization with
the standard Tripos force ﬁeld and 0.005 kcal/mol A˚ energy
gradient convergence criterion using Powell’s method. All the
molecules were assigned with Gasteiger–Huckle charges.36
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A Comparative Molecular Field Analysis (CoMFA) was car-
ried out to evaluate steric and electrostatic ﬁelds using the
QSAR module, and was scaled using the CoMFA standard
in SYBYL-X 1.3. All the analyses were performed by placing
aligned training set molecules in a 3D grid with a spacing of
2.0 A˚. The van der Waals potential and Coulombic terms
which represent steric and electrostatic ﬁelds, respectively,
were calculated using the standard Tripos force ﬁelds. A sp3
hybridized carbon was used as a probe atom to generate the
steric (Lennard–Jones potential) ﬁeld and a charge of +1.0
to generate the electrostatic (Coulomb potential) ﬁeld. The ste-
ric and electrostatic contributions were set at a default cutoff
energy value of 30 kcal/mol. Several CoMFA models were
developed by permutation of molecules between training and
test sets.
3.4. Partial Least Square (PLS) analysis
PLS method was used to correlate CoMFA ﬁelds with biolog-
ical activities of compounds. In this study the cross-validation
(r2cv) was carried out using leave-one-out (LOO) method which
removes one compound from the data set, and its properties
predicted from the model developed using the rest of com-
pounds. In order to increase the speed of the analyses and to
improve noise-to-signal ratio, all the cross-validations were
performed using a column ﬁlter value (d) of 2.0 kcal/mol by
omitting those lattice points whose energy variation is below
this threshold value. After obtaining an optimum number of
components in the cross-validation analysis step, a ﬁnal non-
cross validated analysis was performed using the optimal num-
ber of components obtained from LOO cross-validation step.
To further assess the robustness and the statistical validity of
the obtained models, bootstrapping analysis for 100 runs was
performed. Finally, the model quality was evaluated in terms
of the LOO cross-validated correlation coefﬁcient q2, the non
cross-validation correlation coefﬁcient r2, the predictive corre-
lation coefﬁcient r2pred, the standard error of estimate S value,
and the F-statistic for analysis for F value.
3.5. Predictive ability of CoMFA models
To assess the predictive abilities of the CoMFA model derived
by the training set, biological activities of an external test set
composed of 08 compounds were predicted. The predictive
ability of the model is expressed by the predictive correlation
coefﬁcient r2pred, calculated by the equation as shown below-
r2pred ¼
SD PRESS
SD
where SD is the sum of the squared deviations between the bio-
logical activities of the test set and mean activities of the train-
ing set compounds; PRESS is the sum of the squared
deviations between the actual and predicted activities of the
test compounds.21
3.6. Molecular docking studies
Molecular docking studies were performed inMaestro 9.3 using
Glide v5.8 (Schro¨dinger, LLC, New York, NY, 2010). Allcompounds were built usingMaestro build panel and optimized
to lower energy conformers using Ligprep v2.5 which uses
OPLS_2005 force ﬁeld. Epik v2.3 was used to generate ionized
state of all compounds at target pH 7.0 ± 2.0. The coordinates
for PfDHFR enzyme (PDB ID 1J3J) were taken from RCSB
Protein Data Bank and prepared for docking using ‘protein
preparation wizard’ in Maestro v9.3. Water molecules in the
structures were removed and termini were capped by adding
ACE and NMA residue. The bond orders and formal charges
were added for hetero groups and hydrogens were added to all
atoms in the structure. Side chains that are not close to the bind-
ing cavity and do not participate in salt bridges were neutralized.
After preparation, the structure was reﬁned to optimize the
hydrogen bond network using OPLS_2005 force ﬁeld. This
helps in reorientation of side chain hydroxyl group. Theminimi-
zationwas terminated when the energy converged or the RMSD
reached a maximum cutoff of 0.30 A˚. Grids were then deﬁned
around reﬁned structure by centering on ligand using default
box size. The extra precision (XP) docking mode for all com-
pounds was performed on generated grid of protein structure.37
The ﬁnal evaluation of ligand–protein binding was done
with Glide score (docking score).GScore = a · vdW+ b ·
Coul + Lipo+Hbond+Metal + BuryP+RotB+ Sitewhere,
vdW: – Van der Waal energy; Coul: – Coulomb energy; Lipo: –
Lipophilic contact term; HBond: – Hydrogen-bonding term;
Metal: – Metal-binding term; BuryP: – Penalty for buried polar
groups; RotB: – Penalty for freezing rotatable bonds; Site: –
Polar interactions at the active site; and the Coefﬁcients of
vdW and Coul are: a= 0.065, b= 0.130.
4. Conclusions
The main objective of this study was to develop statistically
robust CoMFA models with good correlation and predictive
powers using anti-plasmodial activity data of triazine
derivatives. The CoMFA model was found to give better
result as demonstrated by its statistical indices (r2cv = 0.656,
r2ncv = 0.996, r
2
bs = 0.999 and r
2
pred = 0.740). The constructed
3D-QSAR models and structure–activity relationship (SAR)
analyses of the compounds used in the study suggested that
an electronegative and bulky substituent at 30-position and
one bulky substituent at C6-position of triazine analogs
are required to design novel inhibitors of Ala16 Val +
Ser108Thr mutant PfDHFR enzyme. The docking studies
provide useful information for understanding the hydrogen-
bonding interactions between the inhibitors and the active
site residues of the Ala16 Val + Ser108Thr mutant PfDHFR
enzyme. The CoMFA model and the docking studies may
afford the guidance for designing new potential DHFR
inhibitors.
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